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Abstract 
Background: Evidence on cerebrospinal fluid (CSF) analysis to demonstrate Alzheimer’s 
disease has not yet been implemented in diagnostic guidelines.  
Methods: We investigated the use of CSF analysis in a survey among all known memory clinics 
in the Netherlands, of which 85 of 113 (75.2%) responded.  
Results: Sixty percent of respondents used CSF analysis, in 5% (median) of patients. The 
analysis almost always confirmed the working diagnosis in 68.4% and sometimes changed it in 
28.2%. Complications occurred very infrequently (0%, median) and were mild. Reasons not to 
perform CSF analysis included the lack of clear recommendations in diagnostic guidelines.  
Conclusions: These results ask for a guideline update to clarify the use of CSF analysis as an 
add-on diagnostic method. 
3 
 
Introduction 
Recent hypothetical models on Alzheimer’s disease (AD) biomarker dynamics regard 
cerebrospinal fluid (CSF) biomarker analysis of amyloid β42 (Aβ42), phosphorylated tau (p-tau) 
and total tau (t-tau) to demonstrate AD as evidence based.[1] Most diagnostic guidelines, 
however, have not yet implemented this evidence. In contrast to the latest AD research criteria,[2] 
the most frequently used AD-criteria, NINCDS-ADRDA and DSM-IV-TR, do not include CSF 
biomarkers. 
 Triggered by the gap between biomarker evidence and guidelines, we aimed to investigate 
the current use of CSF analysis in the diagnostic work up of Memory Clinic (MC) patients and 
the clinician’s opinion on reasons to use CSF analysis. 
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Methods 
A questionnaire was sent to all known MCs in the Netherlands, i.e. all centres known to perform 
early dementia diagnostics in a multidisciplinary context. MCs that were approached were 
requested to check our list of MCs to see if any centres were missing. The questionnaire was 
distributed by e-mail and could be returned by e-mail or on paper. Participants not responding 
within two weeks were approached by phone or in writing. Approval of this study was not needed 
in accordance with local regulations. 
 With respect to CSF analysis, questions were asked about frequency of use; type of 
patients in whom lumbar puncture was performed; influence of the results on diagnosis; reasons 
to apply or not to apply this method; and frequency and type of complications. 
 One hundred and thirteen MCs were approached, of which 85 responded (75.2%), and 84 
completed at least part of the questions on CSF analysis. Sixty-two MCs of these 84 were based 
in general (54) or academic (8) hospitals. 
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Results 
Fifty MCs (59.5% of respondents, 46 hospital based) used CSF analysis, in 5% (median, range 
0.01-75%) of patients, most often in patients suspected of mild dementia (table 1). Most of the 
MCs found that the results almost always confirmed the working diagnosis (68.4%) and hardly 
ever changed it (53.8%), although change was reported to occur sometimes by 28.2% of MCs. 
The results hardly ever contradicted the working diagnosis, according to 61.5% of MCs. 
 Reasons to perform CSF analysis were diagnostic uncertainty; to differentiate between 
dementia types; or to exclude certain diseases such as Creutzfeldt-Jakob disease or neurolues; 
young age of onset; positive family history; the desire for more diagnostic certainty, e.g. in case 
of implications of the diagnosis for the patient’s employment. Research on new biomarkers was 
not mentioned in this sample of memory clinics. Reasons not to perform CSF analysis included 
the lack of clear recommendations in guidelines; not being convinced of the diagnostic 
advantage; other diagnostic methods being more accessible; the procedure being too invasive; the 
presence of contra-indications for lumbar puncture such as an intracerebral tumor or use of 
anticoagulants.  
 Lumbar puncture failed in 0% (median, range 0-10%). Five percent (median, range 0-
50%) of patients refused to undergo lumbar puncture. Complications occurred in 0% (median, 
range 0-10%). Post-puncture headache was the only complication reported.  
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Discussion 
This survey shows that CSF analysis to diagnose dementia has found its way into clinical 
practice, although there is a wide range in the frequency of use. The proportion of centres using 
CSF analysis in the Netherlands is largely the same as the proportion of expert centres across 
Europe using CSF analysis routinely.[3] The analysis was most often found to confirm the 
diagnosis, and not to contradict it, although it sometimes led to a change in diagnosis. We may 
conclude that in clinical practice, CSF analysis is perceived as sufficiently valid to change the 
pre-test probability of AD and of inflammatory diseases, and thus to change the diagnostic 
hypothesis. The biomarkers Aβ42, p-tau and t-tau are analysed in two core laboratories in the 
Netherlands (located in Nijmegen and Amsterdam), of which the Nijmegen laboratory is certified 
as the national reference laboratory for CSF analyses for AD, which diminishes the analytical 
variance that is still seen in AD biomarker analyses among various laboratories. Newsletters with 
reference standards are regularly sent out from the reference centre to reduce heterogeneity in 
interpretation of the biomarker values. However, the interpretation of the data itself could not be 
controlled for in this study.  
 We did not ask MCs to specify the exact analyses that were performed. In an unknown 
proportion of MCs the standard AD biomarkers Aβ42, p-tau and t-tau may have been used, but in 
some MCs other unspecified CSF analyses may have been applied. Chosen analyses depend on 
the clinical context. As shown by the stated reasons to perform CSF analysis, this is both used to 
exclude diseases and to gain more certainty about the presence of AD pathology. The percentages 
of confirmation and change may therefore reflect test characteristics of the analysis, but also the 
selection of patients in whom lumbar puncture is performed. Complications occurred infrequently 
and were mild, which confirms previous reports suggesting high safety of lumbar puncture.[4]  
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 The lack of clear recommendations in dementia guidelines, the uncertainty perceived in 
clinical practice and the heterogeneity of the application of CSF diagnostics found in this survey 
all ask for a dementia guideline update, in which the use of CSF analysis as an add-on diagnostic 
method should be clarified. Although relatively high inter-assay variability of CSF biomarker 
analyses will make it impossible to provide a single reference value in a guideline, a high 
diagnostic performance of CSF biomarkers in diagnosing the neurodegenerative diseases causing 
dementia can be reached when laboratories establish their own reference values.[5,6] Studies on 
cost-effectiveness of CSF analysis and other AD biomarkers are urgently needed to elucidate the 
most efficient diagnostic pathway, considering all currently available diagnostic biomarkers. 
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Table 1. Characteristics of  the type of patients and results of using CSF biomarkers in dementia 
diagnostics in Dutch memory clinics 
 
    Median (range)  No. of MCsa that responded (%b) 
Type of patient 
Subjective complaints  0% (0-75%)  26 (52%) 
Cognitive disorder, no dementia 5% (0-95%)  32 (64%) 
Mild dementia   15% (0-100%)  33 (66%) 
Moderate-severe dementia  2% (0-80%)  29 (58%) 
 
Failing procedure  0% (0-10%)  25 (50%) 
Refusal patient   5% (0-50%)  30 (60%) 
Complications   0% (0-10%)  23 (46%) 
 
CSF confirms diagnosis  N (%c)   38 (76%) 
Never    1 (2.6%) 
Hardly ever   0 (0%) 
Sometimes   11 (28.9%) 
Almost always   26 (68.4%) 
Always    0 (0%) 
CSF changes diagnosis     39 (78%) 
Never    6 (15,4%) 
Hardly ever   21 (53,8%) 
Sometimes   11 (28,2%) 
Almost always   1 (2,6%) 
Always    0 (0%) 
CSF contradicts diagnosis    39 (78%) 
Never    5 (12,8%) 
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Hardly ever   24 (61,5%) 
Sometimes   10 (25,6%) 
Almost always   0 (0%) 
Always    0 (0%) 
 
a MC = memory clinic 
b percentage of the MCs responding to the specific question  
c percentage of the 50 MCs using CSF analysis 
 
 
